Welcome to our dedicated page for NovoCure SEC filings (Ticker: NVCR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on NovoCure's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into NovoCure's regulatory disclosures and financial reporting.
NovoCure Limited filed a current report to disclose that on January 12, 2026 it issued a press release with certain preliminary financial results and other information for the quarter and year ended December 31, 2025. The report explains that the figures in the press release are unaudited, preliminary, based on the company’s good faith estimates, and remain subject to completion of its financial closing procedures and final adjustments, so actual results may differ materially. The press release is furnished as Exhibit 99.1 and the company specifies that this information is being furnished under the securities laws rather than filed for liability purposes.
NovoCure Ltd. (NVCR) reported an insider transaction on Form 4 for its Chief Financial Officer. On 11/04/2025, 7,033 ordinary shares were withheld at $12.23 to satisfy tax obligations from the vesting of Restricted Stock Units. Following this withholding (transaction code F), the CFO directly holds 134,117 shares. The filing notes the action was not discretionary and was approved pursuant to Rules 16b-3(e) and 16b-3(d)(1).
NovoCure Ltd. (NVCR) reported insider activity by Chief Operating Officer Mukund Paravasthu related to RSU vesting tax withholding. On 11/01/2025, the issuer withheld 168 ordinary shares at $12.81 per share. On 11/04/2025, the issuer withheld an additional 2,949 ordinary shares at $12.23 per share. These are coded “F” transactions, reflecting shares withheld to satisfy tax obligations and described as non-discretionary. Following these transactions, Paravasthu directly beneficially owned 80,439 ordinary shares.
NovoCure Ltd (NVCR) reported an insider transaction on a Form 4. The company’s officer, EVP, President, Novocure Oncology, had 966 ordinary shares withheld on 11/01/2025 at $12.81 per share to satisfy tax obligations upon the vesting of Restricted Stock Units (transaction code F).
Following this non-discretionary withholding, the officer beneficially owns 347,745 shares, held directly. The filing indicates it was made by one reporting person.
NovoCure Ltd (NVCR): The company’s Chief Human Resources Officer reported a tax withholding transaction tied to RSU vesting. On 10/31/2025, 752 ordinary shares were withheld under Transaction Code F at $12.82 per share to satisfy withholding obligations. Following the transaction, the officer beneficially owns 163,762 shares, held directly. The filing notes the action was non‑discretionary and approved pursuant to Rules 16b‑3(e) and 16b‑3(d)(1).
NovoCure Limited (NVCR) reported third-quarter 2025 results showing continued top-line growth alongside operating losses. Net revenues were $167,204 (thousands), up 8% year over year, driven by growth in France, Germany and other international markets, partially offset by lower U.S. prior-period claim benefits and $3,300 of FX tailwinds. Gross margin was 73% versus 77% a year ago, reflecting higher array costs, tariffs, and a $2,900 inventory obsolescence charge for Optune Lua arrays.
The company recorded a net loss of $37,270 (thousands) and operating loss of $36,021 (thousands). Cash and cash equivalents were $342,119 with short-term investments of $691,382 as of September 30, 2025. NovoCure drew the Tranche B term loan, bringing its senior secured credit facility borrowings to $200,000, and its 0% Convertible Senior Notes due 2025 carried a current liability of $560,620.
Commercial metrics improved: active patients rose to 4,416 from 4,113, and total prescriptions increased to 1,805 from 1,586. Management highlighted clinical and regulatory milestones, including PANOVA-3 results and ongoing PMA filings for pancreatic cancer (Optune Pax) and brain metastases from NSCLC (Optune Mya), while noting a potential impact from a U.S. government shutdown on FDA and reimbursement timelines.
NovoCure Limited reported that it issued a press release announcing certain financial results for the quarter ended June 30, 2025. The announcement was furnished in an 8-K dated October 30, 2025.
The press release is provided as Exhibit 99.1.
NovoCure Limited filed a current report to highlight a regulatory milestone in Japan. On September 15, 2025, Japan’s Ministry of Health, Labour and Welfare approved NovoCure’s Optune Lua® device for use together with PD-1/PD-L1 inhibitor drugs to treat adult patients with unresectable advanced or recurrent non-small cell lung cancer whose disease has progressed after platinum-based chemotherapy. This expands Optune Lua’s approved treatment setting in Japan for a difficult-to-treat lung cancer population. The company released the news in a press release that is furnished as an exhibit to the report.
NovoCure (NVCR) insider purchase by CEO Ashley Cordova: The filing reports that on 09/05/2025 the reporting person purchased 81,550 ordinary shares in multiple trades at prices ranging from $12.02 to $12.47, with a weighted average price of $12.2239. After the purchases, the reporting person beneficially owned 437,569 shares. The Form 4 identifies Ashley Cordova as Chief Executive Officer and a director, and the filing was signed by an attorney-in-fact on 09/08/2025. The filer notes willingness to provide detailed trade-level prices and quantities on request.
NovoCure Limited reported that its subsidiary Novocure GmbH has decided to terminate the LUNAR-4 clinical trial. LUNAR-4 is a phase 2, single-arm, open-label, multinational study evaluating Tumor Treating Fields used together with pembrolizumab for patients with metastatic non-small cell lung cancer who were previously treated with a PD-1/PD-L1 inhibitor and platinum-based chemotherapy.
The company explains that the availability of real-world evidence will allow it to achieve the trial’s objectives without continuing this interventional clinical study. NovoCure states that this decision is not related to any safety concerns.